OxThera
oxthera.com
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Primary Hyperoxaluria Market to Exhibit Substantial Growth Rate by 2032, Assesses DelveInsight Leading Companies - Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, OxThera, Allena Pharmaceuticals, Biocodex
The primary hyperoxaluria market is anticipated to witness an upsurge in growth in the coming years due to factors such as the increase in the patient pool and the expected entry of emerging.New York, USA, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Primary Hyperox
Read more
Report
OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function
/PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces...
Read more
Report
OxThera announces completion of recruitment in Phase 3 ePHex study with Oxabact in patients with primary hyperoxaluria
Stockholm - 6 April 2020. OxThera AB, a privately-held biopharmaceutical company dedicated to
Read more
Report
OxThera präsentiert auf der Kidney Week 2019 die vollständigen Daten einer 24-Monatsperiode für Oxabact bei Patienten mit primärer Hyperoxalurie Typ 1 (PH1) mit ESRD
Washington (ots/PRNewswire) - OxThera AB, ein privat geführtes biopharmazeutisches Unternehmen, das sich der Verbesserung des Lebens von Menschen mit Primärhyperoxalurie (PH) verschrieben hat, präsentiert
Read more
Report
OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes
Read more
Report
Report
OxThera Announces the Randomization of the First Patient Into its Phase III EPHEX Study With Oxabact
/PRNewswire/ -- OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary...
Read more
Report
OxThera Announces the Randomization of the First Patient Into its Phase III EPHEX Study With Oxabact
/PRNewswire/ -- OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary...
Read more
Report